We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

40 hedge funds and large institutions have $14.9M invested in X4 Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.04% less ownership

Funds ownership: 0.4% → 0.36% (-0.04%)

67% less capital invested

Capital invested by funds: $45.5M → $14.9M (-$30.6M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
7
Increased
16
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$296K
2
AIM
Alambic Investment Management
California
+$287K
3
State Street
State Street
Massachusetts
+$145K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$117K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$110K

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$9.83M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.61M
3
JP Morgan Chase
JP Morgan Chase
New York
-$168K
4
UBS Group
UBS Group
Switzerland
-$32.7K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.54K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$11K – – –
MAM
27
Meeder Asset Management
Ohio
$11K +$17.4K +41 New
AIG
28
American International Group
New York
$6K +$848 +2 +12%
UBS Group
29
UBS Group
Switzerland
$5K -$32.7K -77 -80%
Wells Fargo
30
Wells Fargo
California
$4K +$424 +1 +7%
Barclays
31
Barclays
United Kingdom
$3K +$2.54K +6 +120%
JP Morgan Chase
32
JP Morgan Chase
New York
$2K -$168K -395 -98%
TRCT
33
Tower Research Capital (TRC)
New York
$2K -$2.54K -6 -43%
SO
34
STRS Ohio
Ohio
$2K – – –
Bank of America
35
Bank of America
North Carolina
$2K +$848 +2 +40%
AIP
36
Ameritas Investment Partners
Nebraska
$1K – – –
Legal & General Group
37
Legal & General Group
United Kingdom
$1K – – –
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$237 – – –
Fidelity Investments
39
Fidelity Investments
Massachusetts
– -$2.61M -6,157 -100%
AI
40
Alphabet Inc
California
– -$9.83M -2,508 Closed
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$2K -4 Closed
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
– +$424 +1 New
1
2

XFOR Hedge Fund Activity: Q3 2018 in Review

40 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2018, worth a combined $14.9M — down 67% from $45.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new XFOR positions and 2 closed out — a net gain of 5 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Citigroup, adding an estimated $296K. The largest seller was Alphabet Inc, exiting entirely with an estimated $9.83M sold.

  • 40 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2018, up from 35 in Q2 2018.
  • Funds reported $14.9M of X4 Pharmaceuticals stock for Q3 2018, down 67% quarter-over-quarter.
  • 7 funds opened new X4 Pharmaceuticals positions in Q3 2018 and 2 closed out, a net change of +5 holders.
  • The largest X4 Pharmaceuticals buyer in Q3 2018 was Citigroup, an estimated $296K added.
  • The largest X4 Pharmaceuticals seller in Q3 2018 was Alphabet Inc, an estimated $9.83M sold.

Based on aggregated 13F filings for Q3 2018.